AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 141 min read$SOPH

Xu Zhenyu sold $29K of SOPH

Xu Zhenyu (Chief Scientific Officer) sold 4,000 shares of SOPHiA GENETICS SA (SOPH) at $7.18 on 2026-10-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Xu Zhenyu
Published Oct 14, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SOPH
Bearish
medium confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHBearishLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, offering limited new insight for traders.

02

Market read

Small insider sell with limited trading relevance.

03

What to watch

Insider still holds over half a million shares, indicating continued confidence.

Relevance 2/10Novelty 2/10Timing: after‑hours filing on Oct 13

Background

SEC Form 4 filing discloses an insider transaction for SOPHiA GENETICS SA.

Company-level read

Ticker impact

$SOPHBearishMedium confidence
Context

Chief Scientific Officer sold 4,000 shares for $28.7K via a 10b5‑1 plan, reducing his stake.

Expected impact

likely modest downward pressure as market prices in the insider sale

Evidence & confidence

The sale is small relative to total holdings and follows a pre‑arranged plan, limiting informational value.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale is routine under a 10b5‑1 plan and may have no material impact.

Key entities

  • Company
    SOPHiA GENETICS SA

    Clinical‑data platform provider listed on NASDAQ under SOPH.

  • Executive
    Xu Zhenyu

    Chief Scientific Officer of SOPHiA GENETICS SA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SOPH insider trading history →

Related articles

AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min
AUG 4
$SOPHHighAI 9/10

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

prnewswire.com6 min
AUG 4
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q2 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30,

SEC EDGAR 6-K2 min
AUG 4
$SOPHMed

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

finanznachrichten.de4 min